Results 21 to 30 of about 50 (40)
Drug-eluting stents: a critique [PDF]
Heart, 2008 Despite advances in the design of balloons and stents, restenosis remains a major drawback of coronary angioplasty. Multiple randomised trials have demonstrated that drug-eluting stents (DES) can significantly reduce rates of restenosis by 60-75% across both lesion and patient subsets.
William Wijns, Narbeh Melikian
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Nature Clinical Practice Cardiovascular Medicine, 2008
Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs.
Peter Jüni, Stephan Windecker
openaire +3 more sources
Drug-eluting stents (DESs) effectively reduce angiographic restenosis and the clinical need for repeat revascularization procedures as compared with bare-metal stents. Widely publicized concerns arose recently about the incidence of late and very late stent thrombosis with the use of first-generation DESs.
Peter Jüni, Stephan Windecker
openaire +3 more sources
In-stent Restenosis of drug-eluting Stents
Future Cardiology, 2013Drug-eluting stents (DES) have emerged as an improved alternative to bare-metal stents by demonstrating reduced rates of restenosis and target lesion revascularization. This emergence has led to the unrestricted use of DES for various indications and lesions, and subsequently revealed DES in-stent restenosis as a novel interventional therapeutic ...
Ron Waksman +2 more
openaire +2 more sources
Drug-Eluting Stents in the Elderly [PDF]
Current Treatment Options in Cardiovascular Medicine, 2010 The introduction of drug-eluting stents (DES) in 2003 has had a great impact on the management of coronary artery disease in the United States. The application of DES to older adults, the population with the highest prevalence of and worst prognosis for coronary artery disease, remains relatively more controversial.
Laura Mauri +2 more
openaire +2 more sources
WIREs Nanomedicine and Nanobiotechnology, 2009
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Chris Frethem +8 more
openaire +3 more sources
AbstractThis paper reviews the development of coronary stents from a polymer scientist's view point, and presents the first results of an interdisciplinary team assembled for the development of new stent systems. Poly(styrene‐b‐isobutylene‐b‐styrene) block copolymer (SIBS), a nanostructured thermoplastic elastomer, is used in clinical practice as the ...
Chris Frethem +8 more
openaire +3 more sources
Mathematical Medicine and Biology, 2010
In this study, we consider a family of mathematical models to describe the elution of drug from polymer-coated stents into the arterial wall. Our models include the polymer layer, the media, the adventitia, a possible topcoat polymer layer and atherosclerotic plaque.
McGinty, Sean +3 more
openaire +4 more sources
In this study, we consider a family of mathematical models to describe the elution of drug from polymer-coated stents into the arterial wall. Our models include the polymer layer, the media, the adventitia, a possible topcoat polymer layer and atherosclerotic plaque.
McGinty, Sean +3 more
openaire +4 more sources
2011
Coronary stents have revolutionized the management of patients with obstructive coronary artery disease. This chapter will review the problems associated with percutaneous coronary intervention when performed using balloon angioplasty and bare-metal stents, before discussing the first and second generation drug-eluting stents (DESs).
Scot Garg +2 more
openaire +4 more sources
Coronary stents have revolutionized the management of patients with obstructive coronary artery disease. This chapter will review the problems associated with percutaneous coronary intervention when performed using balloon angioplasty and bare-metal stents, before discussing the first and second generation drug-eluting stents (DESs).
Scot Garg +2 more
openaire +4 more sources
Polymers for Drug Eluting Stents
Current Pharmaceutical Design, 2010Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue.
Ted Parker, Robert Falotico, Vipul Dave
openaire +3 more sources
2013
Advances in the field of stents have revolutionised the treatment of coronary artery diseases. To provide effective treatment for coronary artery disease, a stent has to be deliverable and flexible, cause minimal trauma to the vessel wall, cause minimal inflammatory reaction, endothelialise well, provide scaffolding for the vessel, and finally promote ...
Abraham J. Domb +4 more
openaire +2 more sources
Advances in the field of stents have revolutionised the treatment of coronary artery diseases. To provide effective treatment for coronary artery disease, a stent has to be deliverable and flexible, cause minimal trauma to the vessel wall, cause minimal inflammatory reaction, endothelialise well, provide scaffolding for the vessel, and finally promote ...
Abraham J. Domb +4 more
openaire +2 more sources
The American Journal of Cardiology, 2007
Drug-eluting stents (DESs) held the promise of mitigating, if not abolishing, in-stent restenosis. This led to early adoption and high penetration of DES use in percutaneous coronary intervention (PCI). Outcomes have not demonstrated an improvement in the hard end points of death and myocardial infarction with these devices, but repeat procedures for ...
Tina L. Pinto Slottow, Ron Waksman
openaire +3 more sources
Drug-eluting stents (DESs) held the promise of mitigating, if not abolishing, in-stent restenosis. This led to early adoption and high penetration of DES use in percutaneous coronary intervention (PCI). Outcomes have not demonstrated an improvement in the hard end points of death and myocardial infarction with these devices, but repeat procedures for ...
Tina L. Pinto Slottow, Ron Waksman
openaire +3 more sources